Kesler Norman & Wride LLC Acquires New Holdings in Cencora, Inc. (NYSE:COR)

Kesler Norman & Wride LLC acquired a new stake in shares of Cencora, Inc. (NYSE:COR) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 40,342 shares of the company’s stock, valued at approximately $9,803,000. Cencora makes up 2.1% of Kesler Norman & Wride LLC’s investment portfolio, making the stock its 7th biggest position.

A number of other hedge funds and other institutional investors have also modified their holdings of COR. FORVIS Wealth Advisors LLC bought a new stake in Cencora in the first quarter worth about $736,000. Leeward Investments LLC MA bought a new stake in Cencora in the first quarter worth about $23,148,000. Horizon Bancorp Inc. IN bought a new stake in Cencora in the first quarter worth about $179,000. Retirement Guys Formula LLC bought a new stake in Cencora in the first quarter worth about $1,241,000. Finally, First Trust Direct Indexing L.P. bought a new stake in Cencora in the first quarter worth about $2,502,000. 97.52% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Cencora

In related news, CEO Steven H. Collis sold 10,754 shares of the business’s stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $237.48, for a total value of $2,553,859.92. Following the completion of the sale, the chief executive officer now directly owns 285,088 shares in the company, valued at approximately $67,702,698.24. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CEO Steven H. Collis sold 10,754 shares of the business’s stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $237.48, for a total value of $2,553,859.92. Following the completion of the sale, the chief executive officer now directly owns 285,088 shares in the company, valued at approximately $67,702,698.24. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Robert P. Mauch sold 57,564 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $235.09, for a total value of $13,532,720.76. Following the completion of the sale, the chief operating officer now owns 24,412 shares of the company’s stock, valued at $5,739,017.08. The disclosure for this sale can be found here. Insiders have sold a total of 1,956,675 shares of company stock valued at $422,352,056 in the last 90 days. 15.80% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Robert W. Baird boosted their price target on shares of Cencora from $275.00 to $277.00 and gave the stock an “outperform” rating in a research report on Thursday, May 2nd. StockNews.com downgraded Cencora from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 2nd. SVB Leerink restated an “outperform” rating and set a $275.00 price objective on shares of Cencora in a report on Thursday, June 27th. Finally, Citigroup boosted their price objective on Cencora from $265.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, April 30th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $235.30.

Cencora Stock Down 0.0 %

NYSE:COR traded down $0.01 on Thursday, hitting $222.50. 648,190 shares of the company’s stock traded hands, compared to its average volume of 1,716,663. The company has a current ratio of 0.89, a quick ratio of 0.53 and a debt-to-equity ratio of 3.41. Cencora, Inc. has a 1 year low of $171.65 and a 1 year high of $246.75. The firm has a 50-day moving average price of $227.90 and a 200-day moving average price of $228.39. The company has a market cap of $44.38 billion, a PE ratio of 24.34, a price-to-earnings-growth ratio of 1.55 and a beta of 0.45.

Cencora (NYSE:COR) last released its earnings results on Wednesday, May 1st. The company reported $3.80 earnings per share for the quarter, beating the consensus estimate of $3.65 by $0.15. Cencora had a return on equity of 268.67% and a net margin of 0.67%. The company had revenue of $68.41 billion for the quarter, compared to analysts’ expectations of $70.60 billion. During the same quarter in the previous year, the business posted $3.50 EPS. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. Equities analysts anticipate that Cencora, Inc. will post 13.44 EPS for the current fiscal year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, May 24th. Shareholders of record on Friday, May 10th were paid a dividend of $0.51 per share. The ex-dividend date was Thursday, May 9th. This represents a $2.04 annualized dividend and a yield of 0.92%. Cencora’s dividend payout ratio (DPR) is presently 22.32%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.